Daiichi Sankyo: New data further strengthens important role of LIXIANA (edoxaban) in managing complex patient populations with atrial fibrillation (AF)

Data from the ETNA-AF-Europe Registry provide insights on edoxaban in routine clinical practice in patient subpopulations including those who are frail, with heart failure or insulin-dependent diabetes1

Related Keywords

Wolfgang Schiessl ,Stefan Seyfried ,Daiichi Sankyo ,Daiichi Sankyo Europe ,Daiichi Sankyo Europe Gmb ,University Of Pisa ,European Society Of Cardiology Congress ,Pisa University Hospital ,Sustainable Development Of Society ,Innovative Global Healthcare Company ,European Society Of Cardiology ,European Heart Rhythm Association Practical ,University Cardiology Division ,Edoxaban Clinical Research Programme ,Europe Registry ,European Society ,Sankyo Europe ,Cardiology Congress ,Raffaele De Caterina ,Pisa University ,Vice President ,Medical Affairs ,Specialty Medicines ,Global Healthcare Company Contributing ,Sustainable Development ,Exodaban Treatment ,Atrial Fibrillation ,Heart Rhythm Association Practical Guide ,Non Vitamink Antagonist Oral Anticoagulants ,Sankyo Europe Gmbh ,Communication Lead ,Daiichi ,Sankyo ,Data ,Urther ,Trengthens ,Important ,Sole ,Dixiana ,Edoxaban ,Managing ,Complex ,Patient ,Populations ,Trial ,Defibrillation ,